Ritu Jaiswal

About

Dr Ritu Jaiswal has completed her M.Sc. and a PhD in Medicine from The University of Sydney in 2013. During her PhD, working in a collaborative research team, she contributed to the first time demonstration of the role of membrane vesicles in conferring multidrug resistance in cancer. She then spent 1 year as a Postdoctoral research scientist at University of Technology Sydney. She was later awarded the prestigious and the highly-competitive UTS Chancellor’s Postdoctoral Research Fellowship in 2015. She is currently researching on cancer and immune cell interactions. In addition to her research career, she has been lecturing since 2012 at UTS.

Dr Jaiswal has presented her work at several national and international conferences and has authored over 15 peer-reviewed journal articles and conference proceedings. She has received travel awards provided by the Postgraduate Research Support Scheme, USyD (2012) and by the Australian Society of Biophysics (2010) to present at conferences.She also received the best student oral presentation award at the Australian Physiological Society and Australian Society of Biophysics Joint Scientific Meeting 2010.

She has also reviewed manuscripts for a number of research journals in the field of cancer, microvesicle and multidrug resistance (Future Medicinal Chemistry, J Canc Res Clin Onco, Journal of Pharmacy and Pharmaceutical Sciences, etc.)

Employment

• University of Technology Sydney Chancellor’s Postdoctoral Research Fellow
  2015 - Present
• University of Technology Sydney Postdoctoral Fellow
  2014 - 2015
• University of Technology Sydney Associate Lecturer
  2012 - 2012
• University of Technology Sydney Lecturer/Casual Academic
  2011 - 2016
• University of Sydney Research Assistant
  2009 - 2009

Education

• University of Sydney Doctor of Philosophy
  2009 - 2012
• University of Technology Sydney Master of Science Management
  ? - 2008
• University of Technology Sydney Masters in Applied Science (Molecular Biotechnology)
  ? - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (15)

• Multiple myeloma and persistence of drug resistance in the age of novel drugs
  2016 DOI: 10.3892/ijo.2016.3516
  +Save
• The Role of CD44 and ERM Proteins in Expression and Functionality of P-glycoprotein in Breast Cancer Cells
  Molecules 2016 DOI: 10.3390/molecules21030290
  +Save
• Abstract PR08: Microparticles derived from drug-resistant cells regulate miR-503 and PYK2 to promote migration and invasion in breast cancer
  Clinical Cancer Research 2015
  +Save
• Microparticles in cancer: A review of recent developments and the potential for clinical application
  Seminars in Cell and Developmental Biology 2015 DOI: 10.1016/j.semcdb.2015.03.009
  +Save
• Cellular communication via microparticles: Role in transfer of multidrug resistance in cancer
  Future Oncology 2014 DOI: 10.2217/fon.13.230
  +Save
• Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells
  Frontiers in Oncology 2014 DOI: 10.3389/fonc.2014.00220
  +Save
• Breast Cancer-Derived Microparticles Display Tissue Selectivity in the Transfer of Resistance Proteins to Cells
  PLoS ONE 2013 DOI: 10.1371/journal.pone.0061515
  +Save
• Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance
  European Journal of Pharmacology 2013 DOI: 10.1016/j.ejphar.2013.09.044
  +Save
• Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways
  Pharmacological Research 2013 DOI: 10.1016/j.phrs.2013.07.009
  +Save
• Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits
  Molecular Cancer 2012 DOI: 10.1186/1476-4598-11-37
  +Save